Carbamazepine and levetiracetam-loaded PLGA nanoparticles prepared by nanoprecipitation method: <i>in vitro</i> and <i>in vivo</i> studies

Kandilli, Büşra; Kaplan, Afife Büşra Uğur; Çetin, Meltem; Taspınar, Numan; Ertugrul, Muhammed Sait; Aydin, İsmail Hakkı; Hacımüftüoğlu, Ahmet

doi:10.1080/03639045.2020.1769127

Cited by 17 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the premature carbamazepine metabolism could be prevented by its nanoformulation. This might be beneficial to reduce the conversion of this drug to its 10,11-epoxide metabolite that has been associated with important toxic effects, namely seizure exacerbation, status epilepticus , and hypersensitivity reactions [ 125 , 126 , 127 ]. In addition, the action of sodium valproate can also be limited due to its poor BBB penetration, side effects, and rapid tissue metabolism [ 128 ].…”

Section: Critical Overviewmentioning

confidence: 99%

Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?

et al. 2023

View full text Add to dashboard Cite

Epilepsy is a chronic and complex condition and is one of the most common neurological diseases, affecting about 50 million people worldwide. Pharmacological therapy has been, and is likely to remain, the main treatment approach for this disease. Although a large number of new antiseizure drugs (ASDs) has been introduced into the market in the last few years, many patients suffer from uncontrolled seizures, demanding the development of more effective therapies. Nanomedicines have emerged as a promising approach to deliver drugs to the brain, potentiating their therapeutic index. Moreover, nanomedicine has applied the knowledge of nanoscience, not only in disease treatment but also in prevention and diagnosis. In the current review, the general features and therapeutic management of epilepsy will be addressed, as well as the main barriers to overcome to obtain better antiseizure therapies. Furthermore, the role of nanomedicines as a valuable tool to selectively deliver drugs will be discussed, considering the ability of nanocarriers to deal with the less favourable physical-chemical properties of some ASDs, enhance their brain penetration, reduce the adverse effects, and circumvent the concerning drug resistance.

show abstract

Section: Critical Overviewmentioning

confidence: 99%

Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Polymeric nanoparticles were prepared using the nanoprecipitation method as described previously [20]. Briefly, 15 mg of PLGA was dissolved in 1 ml of dichloromethane (DCM) and was added dropwise to the 1% PVA in an ice bath, and the stirring was continued overnight for the evaporation of the DCM.…”

Section: Preparation and Characterization Of Plga Polymeric Nanoparti...mentioning

confidence: 99%

PLGA nanoparticle loaded with antioxidants and photosensitizer for ROS shock mediated phototherapy of triple negative breast cancer

Buddhiraju,

Balaraman,

Dehariya

et al. 2023

Biomed. Mater.

View full text Add to dashboard Cite

The potential use of antioxidants for photodynamic therapy (PDT) is investigated in this study. PDT causes Reactive oxygen species (ROS)-mediated cell death; on the contrary, antioxidants scavenge ROS. The use of a photosensitizer along with an antioxidant photosensitizer compensates for the loss of ROS due to the use of antioxidant, eventually leading to cell death. In this work, for PDT and photothermal therapy (PTT), we have combined the photosensitizer IR 792 Perchlorate dye with the antioxidants alpha-tocopherol (A) and p-coumaric acid (C) encapsulated in a polymeric nanocarrier (AC IR NPs). We have reported the synthesis of AC IR NPs using Poly Lactic-co-Glycolic Acid (PLGA) by nanoprecipitation method. The size of the polymeric nanoparticle were found to be 80.4 ± 15.6 nm, with a spherical morphology observed by SEM and TEM. The synthesized AC IR NPs demonstrated good biocompatibility in fibroblast cell lines (L929). Furthermore, the efficacy assessment of the as prepared nanosystem in vitro on breast cancer cell lines (4T1) revealed a significant cell death of nearly 80%. This could be attributed to the ROS generation leading to oxidative stress and inhibition of metastasis. This study provides an evidence that the combination of antioxidant drugs along with photosensitizers have the potential to be an effective therapy for treating breast cancer.

show abstract

“…Preclinical evidence has demonstrated that the encapsulation of such drugs in PLGA NPs and SLNs improves both the pharmacokinetic profile and drug efficacy in animal models when compared to free drug formulations. These include galantamine for the treatment of AD [ 91 ]; anti-PD therapies tolcapone, and resveratrol [ 57 , 79 ]; chemotherapies like paclitaxel [ 92 ]; AEDs carbamazepine, and levetiracetam [ 93 ]; anti-depressant drug duloxetine [ 94 ]; atypical antipsychotic lurasidone hydrochloride [ 95 ]; and naloxone, which is used in the treatment of substance abuse disorder [ 96 ].…”

Section: Plga Np and Sln-mediated Drug Delivery In Vivomentioning

confidence: 99%

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

et al. 2023

View full text Add to dashboard Cite

Nanomedicine is currently focused on the design and development of nanocarriers that enhance drug delivery to the brain to address unmet clinical needs for treating neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers are advantageous for delivery to the central nervous system (CNS) due to their safety profiles, drug-loading capacity, and controlled-release properties. Polymer and lipid-based nanoparticles (NPs) are reported to penetrate the blood–brain barrier (BBB) and have been extensively assessed in in vitro and animal models of glioblastoma, epilepsy, and neurodegenerative disease. Since approval by the Food and Drug Administration (FDA) of intranasal esketamine for treatment of major depressive disorder, intranasal administration has emerged as an attractive route to bypass the BBB for drug delivery to the CNS. NPs can be specifically designed for intranasal administration by tailoring their size and coating with mucoadhesive agents or other moieties that promote transport across the nasal mucosa. In this review, unique characteristics of polymeric and lipid-based nanocarriers desirable for drug delivery to the brain are explored in addition to their potential for drug repurposing for the treatment of CNS disorders. Progress in intranasal drug delivery using polymeric and lipid-based nanostructures for the development of treatments of various neurological diseases are also described.

show abstract

Carbamazepine and levetiracetam-loaded PLGA nanoparticles prepared by nanoprecipitation method: in vitro and in vivo studies

Cited by 17 publications

References 39 publications

Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?

Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?

PLGA nanoparticle loaded with antioxidants and photosensitizer for ROS shock mediated phototherapy of triple negative breast cancer

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Contact Info

Product

Resources

About